石药/复星医药/石四药/中生逆市续挫4%-7%财政部稽查药企会计信息真实性
国家财政部联同医保局成立工作组稽查77家药企会计信息真实性。医药板块今天普遍逆市续捱沽,尤其是蓝筹中生制药(01177.HK)及石药(01093.HK)连跌第三天,前者续挫6.8%,报7.1元,逐步考验100天线(7.03元);後者低见11.46元,创近五个月低,现造11.64元,续跌3.8%。
石四药(02005.HK)最低见5.83元,创四个半月低,现造5.91元,续挫4.8%。
复星医药(02196.HK)连跌第六天,今早高开报20.9元欠承接,掉头低见21.05元,创近五个月低,现造21.25元,续挫4.7%,成交增至381万股。
联储局主席鲍威尔昨晚指,会适当采取行动回应贸易争端潜在风险,市场憧憬联储局减息,美股昨晚全面高收急弹近2.1%-2.7%。不过,因应环球贸易紧张局势再次激化等因素,世银将全球今年经济增长预测下调0.3个百分点至2.6%。日经香港5月季调後PMI由48.4,降至46.9,为2016年6月以来最低。恒指扭五连跌,今早跟随外围高开354点或1.3%报27,116,受制10天线(27,130),升幅逐步收窄,最低见26,875,现造26,893,仅弹131点或0.5%,成交额377亿元
财新中国5月服务业PMI降至52.7三个月低,逊於市场预期54。上证及深成扭转连日跌势,今早高开0.7%及近1%,升至2,888及8,851行人止步,掉头回落,前者见2,866,现造2,874,仅弹0.4%;後者曾倒跌低见8,729,现造8,758,仅弹0.1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.